The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

Oxford University Press (OUP) - Tập 15 Số 1 - Trang 2-12 - 2000
Lorenz C. Hofbauer1, Sundeep Khosla1, Colin R. Dunstan2, David L. Lacey2, William J. Boyle2, B. Lawrence Riggs1
1Endocrine Research Unit, Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, U.S.A.
2Amgen, Inc., Thousand Oaks, California U.S.A.

Tóm tắt

Abstract Although multiple hormones and cytokines regulate various aspects of osteoclast formation, the final two effectors are osteoprotegerin ligand (OPG-L)/osteoclast differentiation factor (ODF), a recently cloned member of the tumor necrosis factor superfamily, and macrophage colony–stimulating factor. OPG-L/ODF is produced by osteoblast lineage cells and exerts its biological effects through binding to its receptor, osteoclast differentiation and activation receptor (ODAR)/receptor activator of NF-κB (RANK), on osteoclast lineage cells, in either a soluble or a membrane-bound form, the latter of which requires cell-to-cell contact. Binding results in rapid differentiation of osteoclast precursors in bone marrow to mature osteoclasts and, at higher concentrations, in increased functional activity and reduced apoptosis of mature osteoclasts. The biological activity of OPG-L/ODF is neutralized by binding to osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF), a member of the TNF-receptor superfamily that also is secreted by osteoblast lineage cells. The biological importance of this system is underscored by the induction in mice of severe osteoporosis by targeted ablation of OPG/OCIF and by the induction of osteopetrosis by targeted ablation of OPG-L/ODF or overexpression of OPG/OCIF. Thus, osteoclast formation may be determined principally by the relative ratio of OPG-L/ODF to OPG/OCIF in the bone marrow microenvironment, and alterations in this ratio may be a major cause of bone loss in many metabolic disorders, including estrogen deficiency and glucocorticoid excess. That changes in but two downstream cytokines mediate the effects of large numbers of upstream hormones and cytokines suggests a regulatory mechanism for osteoclastogenesis of great efficiency and elegance.

Từ khóa


Tài liệu tham khảo

Suda, 1992, Modulation of osteoclast differentiation, Endocr Rev, 13, 66

Suda, 1997, Regulation of osteoclast function, J Bone Miner Res, 12, 869, 10.1359/jbmr.1997.12.6.869

Roodman, 1996, Advances in bone biology: The osteoclast, Endocr Rev, 17, 308

Reddy, 1998, Control of osteoclast differentiation, Crit Rev Eukaryot Gene Exp, 8, 1, 10.1615/CritRevEukarGeneExpr.v8.i1.10

Pacifici, 1996, Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis, J Bone Miner Res, 11, 1043, 10.1002/jbmr.5650110802

Manolagas, 1995, Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis, N Engl J Med, 332, 305, 10.1056/NEJM199502023320506

Jilka, 1998, Cytokines, bone remodeling, and estrogen deficiency: A 1998 update, Bone, 23, 75, 10.1016/S8756-3282(98)00077-5

Simonet, 1997, Osteoprotegerin: A novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3

Yasuda, 1998, Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro, Endocrinology, 39, 1329, 10.1210/endo.139.3.5837

Lacey, 1998, Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X

Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotege- rin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc Natl Acad Sci, 95, 3597, 10.1073/pnas.95.7.3597

Wong, 1997, TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells, J Biol Chem, 272, 25190, 10.1074/jbc.272.40.25190

Anderson, 1997, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, 390, 175, 10.1038/36593

O'Brien, 1998, Identification of an OSF-2 binding sitein the murine RANKL/OPGL gene promoter: A potential link between osteoblastogenesis and osteoclastogenesis (abstract 1003), Bone, 23, S149

Gao, 1998, Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF), Biochem Biophys Res Com, 252, 697, 10.1006/bbrc.1998.9643

Hofbauer, 1999, Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis, Endocrinology, 140, in press, 10.1210/endo.140.10.7034

Hofbauer, 1999, Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells, Bone, 24, in press

Takai, 1998, Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells, J Biol Chem, 273, 27091, 10.1074/jbc.273.42.27091

Quinn, 1998, A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro, Endocrinology, 139, 4424, 10.1210/endo.139.10.6331

Matsuzaki, 1998, Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures, Biochem Biophys Res Com, 246, 199, 10.1006/bbrc.1998.8586

Fuller, 1998, TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts, J Exp Med, 188, 997, 10.1084/jem.188.5.997

Burgess, 1999, The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts, J Cell Biol, 145, 527, 10.1083/jcb.145.3.527

Lum, 1999, Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival, J Biol Chem, 274, 13613, 10.1074/jbc.274.19.13613

Yao, 1998, The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells, J Biol Chem, 273, 4119, 10.1074/jbc.273.7.4119

Lea, 1999, Macrophage colony stimulating-factor transcripts are differentially regulated in rat bone-marrow by gender hormones, Endocrinology, 140, 273, 10.1210/endo.140.1.6451

Tsukii, 1998, Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1α,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone, Biochem Biophys Res Com, 246, 337, 10.1006/bbrc.1998.8610

Yamamoto, 1998, Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat, Endocrinology, 139, 4012, 10.1210/endo.139.9.6290

Wong, 1997, TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor, J Exp Med, 186, 2075, 10.1084/jem.186.12.2075

Kong, 1999, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, 397, 315, 10.1038/16852

Deguchi, 1999, Excessive extramedullary hematopoiesis in cbfa1-deficient mice with a congenital lack of bone marrow, Biochem Biophys Res Com, 255, 352, 10.1006/bbrc.1999.0163

Darnay, 1998, Characterization of the intracellular domain of receptor activator of NF-κB (RANK), J Biol Chem, 273, 20551, 10.1074/jbc.273.32.20551

Hsu, 1999, Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proc Natl Acad Sci, 96, 3540, 10.1073/pnas.96.7.3540

Nakagawa, 1998, RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis, Biochem Biophys Res Com, 253, 395, 10.1006/bbrc.1998.9788

Wong, 1998, The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor, J Biol Chem, 273, 28355, 10.1074/jbc.273.43.28355

Iotsova, 1997, Osteopetrosis in mice lacking NF-κB1 and NF-κB2, Nature Med, 3, 1285, 10.1038/nm1197-1285

Wang, 1992, Bone and hematopoietic defects in mice lacking c-fos, Nature, 360, 741, 10.1038/360741a0

Johnson, 1992, Pleiotropic effects of a null mutation in the c-fos proto-oncogene, Cell, 71, 577, 10.1016/0092-8674(92)90592-Z

Arch, 1998, Tumor necrosis factor receptor-associated factors (TRAFs)—A family of adapter proteins that regulates life and death, Genes Dev, 12, 2821, 10.1101/gad.12.18.2821

Galibert, 1998, The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanism of receptor activator of NF-κB, a member of the TNFR superfamily, J Biol Chem, 273, 34120, 10.1074/jbc.273.51.34120

Dadgostar, 1998, An intact zinc finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-κB activation but is dispensible for c-Jun N-terminal kinase signaling, J Biol Chem, 273, 24775, 10.1074/jbc.273.38.24775

Lomaga, 1999, TRAF6-deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling, Genes Dev, 13, 1015, 10.1101/gad.13.8.1015

Darnay, 1999, Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif, J Biol Chem, 274, 7724, 10.1074/jbc.274.12.7724

Tsuda, 1997, Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis, Biochem Biophys Res Com, 234, 137, 10.1006/bbrc.1997.6603

Tan, 1997, Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells, Gene, 204, 35, 10.1016/S0378-1119(97)00509-X

Kwon, 1998, TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption, FASEB J, 12, 845, 10.1096/fasebj.12.10.845

Yun, 1998, OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40, J Immunol, 161, 6113, 10.4049/jimmunol.161.11.6113

Yamaguchi, 1998, Characterization of structural domains of human osteoclastogenesis inhibitory factor, J Biol Chem, 273, 5117, 10.1074/jbc.273.9.5117

Tomoyasu, 1998, Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor, Biochem Biophys Res Com, 245, 382, 10.1006/bbrc.1998.8443

Akatsu, 1998, Osteoclastogenesis-inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast, Biochem Biophys Res Com, 250, 229, 10.1006/bbrc.1998.9294

Vidal, 1998, Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids, J Endocrinol, 159, 191, 10.1677/joe.0.1590191

Hofbauer, 1998, Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines, Biochem Biophys Res Com, 250, 776, 10.1006/bbrc.1998.9394

Hofbauer, 1999, Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells, Endocrinology, 140, 4367, 10.1210/endo.140.9.7131

Vidal, 1998, Osteoprotegerin mRNA is increased by interleukin-α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells, Biochem Biophys Res Com, 248, 696, 10.1006/bbrc.1998.9035

Brändström, 1998, Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells, Biochem Biophys Res Com, 248, 454, 10.1006/bbrc.1998.8993

Murakami, 1998, Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells, Biochem Biophys Res Com, 252, 747, 10.1006/bbrc.1998.9723

Brändström, 1998, Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells, Biochem Biophys Res Com, 247, 338, 10.1006/bbrc.1998.8783

Mizuno, 1998, Structure of the mouse osteoclastogenesis inhibitory factor/osteoprotegerin gene and its expression in embryogenesis, Gene, 215, 339, 10.1016/S0378-1119(98)00295-9

Miyamoto, 1998, Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts, Biochem Biophys Res Com, 242, 703, 10.1006/bbrc.1997.8046

Emery, 1998, Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL, J Biol Chem, 273, 14363, 10.1074/jbc.273.23.14363

Tan, 1997, Recombinant osteoprotegerin (OPG), a novel TNF-receptor family member, inhibits in vitro murine osteoclast formation from bone marrow precursors (abstract P213), J Bone Miner Res, 12, S155

Hakeda, 1998, Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts, Biochem Biophys Res Com, 251, 796, 10.1006/bbrc.1998.9523

Bucay, 1998, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev, 12, 1260, 10.1101/gad.12.9.1260

Mizuno, 1998, Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin, Biochem Biophys Res Com, 247, 610, 10.1006/bbrc.1998.8697

Barengolts, 1998, Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women, Calcif Tissue Int, 62, 209, 10.1007/s002239900419

Chenu, 1988, Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures, Proc Natl Acad Sci, 85, 5683, 10.1073/pnas.85.15.5683

Pfeilschifter, 1988, Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures, J Clin Invest, 82, 680, 10.1172/JCI113647

Dinarello, 1996, Biologic basis for interleukin-1 in disease, Blood, 87, 2095, 10.1182/blood.V87.6.2095.bloodjournal8762095

Hing, 1998, Mechanisms by which NF-κB regulates osteoclast numbers (abstract 1172), Bone, 23, S190

O'Brien, 1999, STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1.25-dihydroxyvitamin D3 or parathyroid hormone, J Biol Chem, 274, 19301, 10.1074/jbc.274.27.19301

Adebanjo, 1998, Mode of action of interleukin-6 on mature osteoclasts. Novel interactions with extracellular Ca2+ sensing in the regulation of osteoclastic bone resorption, J Cell Biol, 142, 1347, 10.1083/jcb.142.5.1347

Riggs, 1998, A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men, J Bone Miner Res, 13, 763, 10.1359/jbmr.1998.13.5.763

Spelsberg, 1999, The actions and interactions of sex steroids and growth factors/cytokines on the skeleton, Mol Enocrinol, 13, 819, 10.1210/mend.13.6.0299

Parfitt, 1996, A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates, J Bone Miner Res, 11, 150, 10.1002/jbmr.5650110203

Kitazawa, 1994, Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice, J Clin Invest, 94, 2397, 10.1172/JCI117606

Kimble, 1997, The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice, J Bone Miner Res, 12, 935, 10.1359/jbmr.1997.12.6.935

Jilka, 1992, Increased osteoclast development after estrogen loss: mediation by interleukin-6, Science, 257, 88, 10.1126/science.1621100

Kimble, 1996, Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor, J Biol Chem, 271, 28890, 10.1074/jbc.271.46.28890

Kawaguchi, 1995, Ovariectomy enhances and estrogen replacement inhibits the activity of bone marrow factors that stimulate prostaglandin production in cultured mouse calvariae, J Clin Invest, 96, 539, 10.1172/JCI118066

Pacifici, 1989, Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy, J Clin Endocrinol Metab, 77, 1135

Oursler, 1994, Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells, Proc Natl Acad Sci, 91, 5227, 10.1073/pnas.91.12.5227

Hughes, 1997, Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta, Nature Med, 2, 1132, 10.1038/nm1096-1132

Oursler, 1991, Modulation of transforming growth factor-β production in normal human osteoblast-like cells by 17β-estradiol and parathyroid hormone, Endocrinology, 129, 3313, 10.1210/endo-129-6-3313

Robinson, 1996, Osteoclasts and transforming growth factor-β: Estrogen-mediated isoform-specific regulation of production, Endocrinology, 137, 615, 10.1210/endo.137.2.8593810

Yano, 1999, Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis, J Bone Miner Res, 14, 518, 10.1359/jbmr.1999.14.4.518

Arrighi, 1998, Osteoprotegerin serum levels in healthy volunteers (abstract T411), Bone, 23, S298

Lukert, 1990, Glucocorticoid-induced osteoporosis: pathogenesis and management, Ann Intern Med, 112, 352, 10.7326/0003-4819-112-5-352

Reid, 1997, Glucocorticoid osteoporosis—Mechanisms and management, Eur J Endocrinol, 137, 209, 10.1530/eje.0.1370209

Conaway, 1996, Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone, J Bone Miner Res, 11, 1419, 10.1002/jbmr.5650111008

Kaji, 1997, Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2, J Bone Miner Res, 12, 734, 10.1359/jbmr.1997.12.5.734

Gronowicz, 1990, Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro, J Bone Miner Res, 5, 1223, 10.1002/jbmr.5650051206

Chiodini, 1998, Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome, J Clin Endocrinol Metab, 83, 1863

Riggs, 1966, Quantitative microradiographic study of bone remodeling in Cushing's syndrome, Metabolism, 15, 773, 10.1016/0026-0495(66)90169-7

Dempster, 1989, Bone histomorphometry in glucocorticoid-induced osteoporosis, J Bone Miner Res, 4, 137, 10.1002/jbmr.5650040202

Bornefalk, 1998, Serum levels of osteoprotegerin: Effects of glucocorticoids and growth hormone (abstract F321), Bone, 23, S486

Dunstan, 1997, Osteoprotegerin (OPG), a novel TNF-receptor family member, profoundly inhibits endosteal bone resorption due to growth, humoral hypercalcemia of malignancy, and interleukin 1 (abstract 134), J Bone Miner Res, 12, S136

Akatsu, 1998, Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy, Bone, 23, 495, 10.1016/S8756-3282(98)00141-0

Thông tin
Thông tin xuất bản

Oxford University Press (OUP)

Tập 15 Số 1

2-12

Thông tin tác giả